Articles & guides

14 Jun 2026

Ready to Start Pembrolizumab? Your Next Steps Explained

From eligibility check to first injection - a clear walkthrough of what the process looks like once you decide to go ahead.

12 Jun 2026

Durable Remission: Why Some Immunotherapy Responses Last Years

A look at why pembrolizumab can produce long-lasting responses - and what the data tells us about how durable they can be.

10 Jun 2026

Monitoring During Pembrolizumab: What Tests Will I Need?

Blood tests, imaging, and clinical check-ins - what monitoring looks like during treatment and why it matters.

8 Jun 2026

Is Home-Based Pembrolizumab Safe? Understanding the Evidence

What the clinical evidence says about safety when pembrolizumab is administered at home, and how our oversight model works.

6 Jun 2026

Pembrolizumab Cost in the UK: What You Need to Know

NHS availability, private treatment pricing, and why transparency about cost matters before any commitment is made.

4 Jun 2026

Long-Term Outcomes in Cancer Immunotherapy: What the Data Shows

Five-year survival data, durable response rates, and what long-term follow-up from the KEYNOTE programme tells us.

31 May 2026

Five Questions to Ask Before Starting Pembrolizumab

The questions that matter most when you are deciding whether to go ahead - and what good answers look like.

27 May 2026

The Pembrolizumab Injection: What Happens During Each Visit

A plain-English explanation of what a home treatment visit actually involves - from arrival to departure.

23 May 2026

Checkpoint Inhibitors: How a New Class of Cancer Drug Works

What immune checkpoints are, how checkpoint inhibitor drugs release them, and where pembrolizumab fits in this class.

19 May 2026

What Happens on Your Welcome Call with Our Oncologist?

What the call covers, who you speak to, how long it takes, and what happens afterwards - with no obligation to proceed.

15 May 2026

Pembrolizumab for Bladder Cancer: An Overview

The evidence for pembrolizumab in urothelial carcinoma, including KEYNOTE-052 and KEYNOTE-045 trial results.

11 May 2026

Why Treatment Setting Affects Quality of Life During Cancer Care

What research tells us about the psychological and practical impact of where you receive treatment - and why home matters.

7 May 2026

What to Expect From Your Eligibility Check

How the questionnaire works, what the oncologist reviews, and what a typical outcome looks like within 24 hours.

3 May 2026

Pembrolizumab for Head and Neck Cancer: Current Evidence

How pembrolizumab is used in head and neck squamous cell carcinoma, and what KEYNOTE-048 showed in the first-line setting.

29 Apr 2026

How Your Immune System Can Fight Cancer

The biology behind cancer immunosurveillance - why the immune system sometimes misses tumours, and how immunotherapy helps it find them.

25 Apr 2026

Subcutaneous vs Intravenous Pembrolizumab: What Changed

What the KEYNOTE-D18 trial established about bioequivalence, and why the subcutaneous formulation enables home-based care.

21 Apr 2026

Who Is Eligible for Pembrolizumab? Understanding the Criteria

Cancer type, PD-L1 score, performance status, and other factors that determine whether pembrolizumab is appropriate for you.

17 Apr 2026

Managing Side Effects of Pembrolizumab: A Practical Guide

What immune-related adverse events are, how to recognise early signs, and how they are managed during treatment.

13 Apr 2026

Pembrolizumab for Melanoma: What Patients Need to Know

Five-year survival data, KEYNOTE-001 results, adjuvant use, and BRAF considerations for melanoma patients.

9 Apr 2026

Pembrolizumab for Non-Small Cell Lung Cancer: The Evidence

KEYNOTE-024 and KEYNOTE-189 outcomes, the role of PD-L1 in NSCLC, and what the five-year survival data shows.

5 Apr 2026

How Immunotherapy Differs from Chemotherapy

The mechanism, side effect profile, and response durability of immunotherapy compared to traditional chemotherapy.

1 Apr 2026

What the KEYNOTE Trials Tell Us About Pembrolizumab

An overview of the landmark KEYNOTE clinical trial programme and what its data shows across cancer types.

28 Mar 2026

PD-L1 Expression Explained: Why It Determines Your Eligibility

What PD-L1 is, how it is measured, what TPS and CPS scoring means, and why your result matters for treatment decisions.

24 Mar 2026

Pembrolizumab at Home vs Hospital: What Is the Difference?

How the subcutaneous formulation compares to the traditional IV route, and what moving treatment home actually involves.

20 Mar 2026

What Is Pembrolizumab? A Plain-English Guide

How pembrolizumab works, what the PD-1 checkpoint does, which cancers it treats, and what the subcutaneous formulation means for patients.

16 Mar 2026

Can Pembrolizumab Be Combined with Other Cancer Treatments?

Pembrolizumab combinations with chemotherapy, targeted therapy, and other immunotherapy drugs - what the evidence supports across different cancer types.

12 Mar 2026

Pembrolizumab for Cervical Cancer: What Patients Need to Know

How pembrolizumab is used in recurrent or metastatic cervical cancer, KEYNOTE-826 results, and the role of PD-L1 CPS testing.

8 Mar 2026

How to Read a Pathology Report: A Patient's Guide

What a pathology report contains, why it matters for pembrolizumab eligibility, and how to interpret the language your oncologist uses.

4 Mar 2026

Pembrolizumab for Endometrial Cancer: Current Evidence

KEYNOTE-868 results, the role of MMR and MSI testing, and how pembrolizumab is changing outcomes in advanced endometrial cancer.

28 Feb 2026

MSI-H and dMMR: What These Biomarkers Mean for Your Treatment

Microsatellite instability and mismatch repair deficiency explained - and why these biomarkers predict strong pembrolizumab response across cancer types.

24 Feb 2026

Preparing for Your First Pembrolizumab Treatment

What to arrange before starting, what to bring on the day, and how to prepare your home environment for subcutaneous treatment.

20 Feb 2026

How Is Pembrolizumab Prescribed in the UK?

The prescription pathway for pembrolizumab - from diagnosis and testing to treatment authorisation by a consultant oncologist.

16 Feb 2026

Pembrolizumab and Fatigue: Causes and Management

Why fatigue occurs during pembrolizumab, how it differs from chemotherapy-related fatigue, and practical approaches to managing energy levels.

12 Feb 2026

Response, Remission, Cure: What Do These Terms Really Mean?

Clear definitions of the key terms oncologists use to describe how a cancer is behaving - and what they mean for your treatment decisions.

8 Feb 2026

Pembrolizumab for Oesophageal Cancer: An Overview

KEYNOTE-590 and KEYNOTE-180 trial results, CPS thresholds, and how pembrolizumab fits into oesophageal cancer treatment pathways.

4 Feb 2026

Tumour Mutation Burden: A Newer Biomarker for Immunotherapy

What tumour mutation burden measures, how it differs from PD-L1, and when it is used to guide pembrolizumab treatment decisions.

31 Jan 2026

A Family Member's Guide to Home Cancer Treatment

What families and carers need to know about supporting a loved one through home-based pembrolizumab - practical, honest, and clear.

27 Jan 2026

Pembrolizumab and Thyroid Function: What to Monitor

Immune-related thyroid dysfunction is common during pembrolizumab. How it presents, how it is detected, and what treatment looks like.

23 Jan 2026

Second-Line Cancer Treatment: When Is Pembrolizumab Used?

How pembrolizumab fits into the second-line treatment landscape across different cancer types - and what changes in the second-line setting.

19 Jan 2026

Pembrolizumab for Triple-Negative Breast Cancer

KEYNOTE-522 and KEYNOTE-355 data, the role of CPS in TNBC, and how immunotherapy has changed the treatment landscape for this difficult subtype.

15 Jan 2026

What Does an Oncology Nurse Do?

The role of the oncology nurse in home pembrolizumab treatment - qualifications, what they do at each visit, and how clinical oversight works.

11 Jan 2026

How Long Does Pembrolizumab Treatment Last?

Treatment duration, maximum cycle numbers, when treatment is stopped for response or toxicity, and what happens after a full course.

7 Jan 2026

Pembrolizumab for Gastric and GOJ Cancer

KEYNOTE-859 and KEYNOTE-811 results, CPS and HER2 testing in gastric cancer, and what combination treatment looks like in practice.

31 Dec 2025

A Patient's Guide to Understanding Clinical Trial Data

What trial phases mean, how overall survival and response rate differ, and how to interpret what the evidence means for your own situation.

27 Dec 2025

What Is Performance Status and Why Does It Matter?

The ECOG scale, what each grade means, and why performance status is one of the key factors in pembrolizumab eligibility.

23 Dec 2025

Skin Reactions from Pembrolizumab: What to Expect

How rash and other skin reactions present during pembrolizumab, how severity is graded, and when to seek urgent medical attention.

19 Dec 2025

Pembrolizumab and Steroids: Why Corticosteroids Are Used

Why corticosteroids are the main treatment for immune-related adverse events - and whether they affect how well pembrolizumab works.

15 Dec 2025

Complete Response vs Partial Response: What Do They Mean?

RECIST criteria, complete and partial response defined, stable disease, progressive disease, and how immunotherapy adds the complication of pseudoprogression.

11 Dec 2025

Living Well During Cancer Treatment

Nutrition, exercise, sleep, and emotional wellbeing during pembrolizumab - practical guidance grounded in the available evidence.

7 Dec 2025

What Is a Subcutaneous Injection?

A plain-English explanation of subcutaneous injections - what they are, how they differ from IV infusions, and what a home treatment visit involves.